BGNE Stock Recent News
BGNE LATEST HEADLINES
BeiGene aims to tap the area's life sciences talent pool.
BeiGene, Ltd. (BGNE) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
If you are looking for stocks that are well positioned to maintain their recent uptrend, BeiGene, Ltd. (BGNE) could be a great choice.
The year 2022 proved to be the worst calendar year for the S&P 500 since 2008.
The Chinese pharmaceutical stock is experiencing a comeback.
The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.
BeiGene's shares are down this year, but it has two potential blockbusters.